CD39 transforming cancer therapy by modulating tumor microenvironment.
Cancer Lett
; 597: 217072, 2024 Aug 10.
Article
in En
| MEDLINE
| ID: mdl-38885807
ABSTRACT
CD39 is a pivotal enzyme in cancer, regulating immune response and tumor progression via extracellular ATP and adenosine in the tumor microenvironment (TME). Beyond its established immunoregulatory function, CD39 influences cancer cell angiogenesis and metabolism, opening new frontiers for therapeutic interventions. Current research faces gaps in understanding CD39's full impact across cancer types, with ongoing debates about its potential beyond modulating immune evasion. This review distills CD39's multifaceted roles, examining its dual actions and implications for cancer prognosis and treatment. We analyze the latest therapeutic strategies, highlighting the need for an integrated approach that combines molecular insights with TME dynamics to innovate cancer care. This synthesis underscores CD39's integral role, charting a course for precision oncology that seeks to unravel controversies and harness CD39's therapeutic promise for improved cancer outcomes.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Apyrase
/
Tumor Microenvironment
/
Neoplasms
Limits:
Animals
/
Humans
Language:
En
Journal:
Cancer Lett
/
Cancer lett
/
Cancer letters
Year:
2024
Document type:
Article
Country of publication:
Irlanda